+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pulmonary Arterial Hypertension Market and Forecast Analysis to 2025

  • ID: 3797417
  • Drug Pipelines
  • October 2018
  • Region: Global
  • 489 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Pulmonary arterial hypertension is one of a group of rare and life-threatening diseases collectively known as pulmonary hypertension (PH). Each PH subgroup shares similar pathophysiology, clinical presentation, and therapeutic approaches. The diseases are characterized by abnormal vascular proliferation and remodeling of the small pulmonary arteries and arterioles, vasoconstriction, and in situ thrombosis. This leads to increased pulmonary arterial pressure and localized hypertension, which can eventually result in heart failure.

Market Snapshot
  • Label expansions beyond PAH and evidence championing polypharmacy drive market expansion, with Opsumit and Uptravi leading.
  • Physicians indicate consistent prescribing across PH subgroups, with increasing adoption of combination therapies.
  • The combined disease burden of PH was close to 0.4 million in 2017.
  • Johnson & Johnson will dominate the market with new best-in-class drugs Opsumit and Uptravi amenable to combination use.
  • With limited sales forecast, further data are essential to consolidate niche pipeline drugs’ clinical profiles.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: PULMONARY HYPERTENSION (Published on 29 October 2018)
OVERVIEW
RECENT FORECAST UPDATES
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE: ADCIRCA
PRODUCT PROFILE: ADEMPAS
PRODUCT PROFILE (LATE STAGE): INOPULSE
PRODUCT PROFILE: LETAIRIS
PRODUCT PROFILE: OPSUMIT
PRODUCT PROFILE: ORENITRAM
PRODUCT PROFILE: REMODULIN
PRODUCT PROFILE: REVATIO
PRODUCT PROFILE: TRACLEER
PRODUCT PROFILE: TYVASO
PRODUCT PROFILE: UPTRAVI
PRODUCT PROFILE (LATE STAGE): BARDOXOLONE METHYL
PRODUCT PROFILE (LATE STAGE): ESUBERAPROST
PRODUCT PROFILE (LATE STAGE): RALINEPAG

TREATMENT: PULMONARY HYPERTENSION (Published on 05 January 2017)
OVERVIEW
EXECUTIVE SUMMARY
PRIMARY RESEARCH METHODOLOGY
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
PRESCRIBING TRENDS
UNMET NEEDS IN PULMONARY HYPERTENSION

EPIDEMIOLOGY: PULMONARY HYPERTENSION (Published on 03 July 2018)
OVERVIEW
DISEASE BACKGROUND
METHODOLOGY
FORECAST
BIBLIOGRAPHY
APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: PULMONARY HYPERTENSION (Published on 29 October 2018)
OVERVIEW
PRODUCT OVERVIEW
PRODUCT PROFILE: ADCIRCA
PRODUCT PROFILE: ADEMPAS
PRODUCT PROFILE: LETAIRIS
PRODUCT PROFILE: OPSUMIT
PRODUCT PROFILE: ORENITRAM
PRODUCT PROFILE: REMODULIN
PRODUCT PROFILE: REVATIO
PRODUCT PROFILE: TRACLEER
PRODUCT PROFILE: TYVASO
PRODUCT PROFILE: UPTRAVI

PIPELINE: PULMONARY HYPERTENSION (Published on 29 October 2018)
OVERVIEW
CLINICAL PIPELINE OVERVIEW
ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
PRODUCT PROFILE (LATE STAGE): AURORA-GT
PRODUCT PROFILE (LATE STAGE): INOPULSE
PRODUCT PROFILE (LATE STAGE): BARDOXOLONE METHYL
PRODUCT PROFILE (LATE STAGE): ESUBERAPROST
PRODUCT PROFILE (LATE STAGE): RALINEPAG

LIST OF FIGURES
Figure 1: Pulmonary hypertension – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for pulmonary hypertension
Figure 3: PH market sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: PH market sales across the US, Japan, and five major EU markets, by PH subtype, 2016–25
Figure 5: PH market sales across the US, Japan, and five major EU markets, by class, 2016–25
Figure 6: PH market sales across the US, Japan, and five major EU markets, by formulation, 2016–25
Figure 7: Sales of top brands and pipeline launches for PH across the US, Japan, and five major EU markets, by brand, 2016–25
Figure 8: Methodology flow for The authors PH forecast
Figure 9: Price sources and calculations, by country
Figure 10: Adcirca for pulmonary hypertension – SWOT analysis
Figure 11: The authors drug assessment summary of Adcirca for pulmonary hypertension
Figure 12: The authors drug assessment summary of Adcirca for pulmonary hypertension
Figure 13: Adcirca sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Adempas for pulmonary hypertension – SWOT analysis
Figure 15: The authors drug assessment summary of Adempas for pulmonary hypertension
Figure 16: The authors drug assessment summary of Adempas for pulmonary hypertension
Figure 17: Adempas sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 18: INOpulse for pulmonary hypertension – SWOT analysis
Figure 19: The authors drug assessment summary of INOpulse for pulmonary hypertension
Figure 20: The authors drug assessment summary of INOpulse for pulmonary hypertension
Figure 21: INOpulse sales for pulmonary hypertension in the US, 2016–25
Figure 22: Letairis for pulmonary hypertension – SWOT analysis
Figure 23: The authors drug assessment summary of Letairis for pulmonary hypertension
Figure 24: The authors drug assessment summary of Letairis for pulmonary hypertension
Figure 25: Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 26: Opsumit for pulmonary hypertension – SWOT analysis
Figure 27: The authors drug assessment summary of Opsumit for pulmonary hypertension
Figure 28: The authors drug assessment summary of Opsumit for pulmonary hypertension
Figure 29: Opsumit sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 30: Orenitram for pulmonary hypertension – SWOT analysis
Figure 31: The authors drug assessment summary of Orenitram for pulmonary hypertension
Figure 32: The authors drug assessment summary of Orenitram for pulmonary hypertension
Figure 33: Orenitram sales for pulmonary hypertension across the US and five major EU markets, by country, 2016–25
Figure 34: Remodulin for pulmonary hypertension – SWOT analysis
Figure 35: The authors drug assessment summary of Remodulin for pulmonary hypertension
Figure 36: The authors drug assessment summary of Remodulin for pulmonary hypertension
Figure 37: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country, 2016–25
Figure 38: Revatio for pulmonary hypertension – SWOT analysis
Figure 39: The authors drug assessment summary of Revatio for pulmonary hypertension
Figure 40: The authors drug assessment summary of Revatio for pulmonary hypertension
Figure 41: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 42: Tracleer for pulmonary hypertension – SWOT analysis
Figure 43: The authors drug assessment summary of Tracleer for pulmonary hypertension
Figure 44: The authors drug assessment summary of Tracleer for pulmonary hypertension
Figure 45: Tracleer sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 46: Tyvaso for pulmonary hypertension – SWOT analysis
Figure 47: The authors drug assessment summary of Tyvaso for pulmonary hypertension
Figure 48: The authors drug assessment summary of Tyvaso for pulmonary hypertension
Figure 49: Tyvaso sales for pulmonary hypertension in the US, 2016–25
Figure 50: Uptravi for pulmonary hypertension – SWOT analysis
Figure 51: The authors drug assessment summary of Uptravi for pulmonary hypertension
Figure 52: The authors drug assessment summary of Uptravi for pulmonary hypertension
Figure 53: Uptravi sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 54: Bardoxolone methyl for pulmonary hypertension – SWOT analysis
Figure 55: The authors drug assessment summary of bardoxolone methyl for pulmonary hypertension
Figure 56: The authors drug assessment summary of bardoxolone methyl for pulmonary hypertension
Figure 57: Bardoxolone methyl sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 58: Esuberaprost for pulmonary hypertension – SWOT analysis
Figure 59: The authors drug assessment summary of esuberaprost for pulmonary hypertension
Figure 60: The authors drug assessment summary of esuberaprost for pulmonary hypertension
Figure 61: Esuberaprost sales for pulmonary hypertension in the US, 2016–25
Figure 62: Ralinepag for pulmonary hypertension – SWOT analysis
Figure 63: The authors drug assessment summary of ralinepag for pulmonary hypertension
Figure 64: The authors drug assessment summary of ralinepag for pulmonary hypertension
Figure 65: Ralinepag sales for pulmonary hypertension across the US and five major EU markets, by country, 2016–25
Figure 66: Surveyed respondents’ pulmonary hypertension patient caseload by clinical group
Figure 67: Surveyed respondents’ pulmonary arterial hypertension patient caseload by functional class
Figure 68: Pulmonary arterial hypertension treatment rates with PAH-specific therapy, by severity
Figure 69: Top five therapies among functional class I pulmonary hypertension patients, by country (%)
Figure 70: Top five therapies among functional class II pulmonary hypertension patients, by country (%)
Figure 71: Top five therapies among functional class III pulmonary hypertension patients, by country (%)
Figure 72: Top five therapies among functional class IV pulmonary hypertension patients, by country (%)
Figure 73: Pulmonary hypertension treatment rates with PAH-specific therapy, by severity and country
Figure 74: Top five therapies among pulmonary hypertension due to left heart disease patients, by country (%)
Figure 75: Top five therapies among pulmonary hypertension due to lung disease patients, by country (%)
Figure 76: Top five therapies among chronic thromboembolic pulmonary hypertension patients, by country (%)
Figure 77: Top five therapies among pulmonary hypertension with unclear and/or multifactorial mechanisms patients, by country (%)
Figure 78: Compliance rates of pulmonary hypertension patients, by therapy type and country
Figure 79: Key unmet needs for pulmonary hypertension
Figure 80: Adcirca for pulmonary hypertension – SWOT analysis
Figure 81: The authors drug assessment summary of Adcirca for pulmonary hypertension
Figure 82: The authors drug assessment summary of Adcirca for pulmonary hypertension
Figure 83: Adcirca sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 84: Adempas for pulmonary hypertension – SWOT analysis
Figure 85: The authors drug assessment summary of Adempas for pulmonary hypertension
Figure 86: The authors drug assessment summary of Adempas for pulmonary hypertension
Figure 87: Adempas sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 88: Letairis for pulmonary hypertension – SWOT analysis
Figure 89: The authors drug assessment summary of Letairis for pulmonary hypertension
Figure 90: The authors drug assessment summary of Letairis for pulmonary hypertension
Figure 91: Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 92: Opsumit for pulmonary hypertension – SWOT analysis
Figure 93: The authors drug assessment summary of Opsumit for pulmonary hypertension
Figure 94: The authors drug assessment summary of Opsumit for pulmonary hypertension
Figure 95: Opsumit sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 96: Orenitram for pulmonary hypertension – SWOT analysis
Figure 97: The authors drug assessment summary of Orenitram for pulmonary hypertension
Figure 98: The authors drug assessment summary of Orenitram for pulmonary hypertension
Figure 99: Orenitram sales for pulmonary hypertension across the US and five major EU markets, by country, 2016–25
Figure 100: Remodulin for pulmonary hypertension – SWOT analysis
Figure 101: The authors drug assessment summary of Remodulin for pulmonary hypertension
Figure 102: The authors drug assessment summary of Remodulin for pulmonary hypertension
Figure 103: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country, 2016–25
Figure 104: Revatio for pulmonary hypertension – SWOT analysis
Figure 105: The authors drug assessment summary of Revatio for pulmonary hypertension
Figure 106: The authors drug assessment summary of Revatio for pulmonary hypertension
Figure 107: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 108: Tracleer for pulmonary hypertension – SWOT analysis
Figure 109: The authors drug assessment summary of Tracleer for pulmonary hypertension
Figure 110: The authors drug assessment summary of Tracleer for pulmonary hypertension
Figure 111: Tracleer sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 112: Tyvaso for pulmonary hypertension – SWOT analysis
Figure 113: The authors drug assessment summary of Tyvaso for pulmonary hypertension
Figure 114: The authors drug assessment summary of Tyvaso for pulmonary hypertension
Figure 115: Tyvaso sales for pulmonary hypertension in the US, 2016–25
Figure 116: Uptravi for pulmonary hypertension – SWOT analysis
Figure 117: The authors drug assessment summary of Uptravi for pulmonary hypertension
Figure 118: The authors drug assessment summary of Uptravi for pulmonary hypertension
Figure 119: Uptravi sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 120: Aurora-GT for pulmonary hypertension – SWOT analysis
Figure 121: INOpulse for pulmonary hypertension – SWOT analysis
Figure 122: The authors drug assessment summary of INOpulse for pulmonary hypertension
Figure 123: The authors drug assessment summary of INOpulse for pulmonary hypertension
Figure 124: INOpulse sales for pulmonary hypertension in the US, 2016–25
Figure 125: Bardoxolone methyl for pulmonary hypertension – SWOT analysis
Figure 126: The authors drug assessment summary of bardoxolone methyl for pulmonary hypertension
Figure 127: The authors drug assessment summary of bardoxolone methyl for pulmonary hypertension
Figure 128: Bardoxolone methyl sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
Figure 129: Esuberaprost for pulmonary hypertension – SWOT analysis
Figure 130: The authors drug assessment summary of esuberaprost for pulmonary hypertension
Figure 131: The authors drug assessment summary of esuberaprost for pulmonary hypertension
Figure 132: Esuberaprost sales for pulmonary hypertension in the US, 2016–25
Figure 133: Ralinepag for pulmonary hypertension – SWOT analysis
Figure 134: The authors drug assessment summary of ralinepag for pulmonary hypertension
Figure 135: The authors drug assessment summary of ralinepag for pulmonary hypertension
Figure 136: Ralinepag sales for pulmonary hypertension across the US and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: PH market sales across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: PH market sales across the US, Japan, and five major EU markets, by PH subtype ($m), 2016–25
Table 3: PH market sales across the US, Japan, and five major EU markets, by class ($m), 2016–25
Table 4: PH market sales across the US, Japan, and five major EU markets, by formulation ($m), 2016–25
Table 5: Sales of top brands and pipeline launches for PH across the US, Japan, and five major EU markets, by brand ($m), 2016–25
Table 6: Exchange rates used for calculating prices
Table 7: Cardiologists and pulmonologists surveyed for the pulmonary hypertension primary research study, 2016
Table 8: Adcirca drug profile
Table 9: Adcirca pivotal trial data in pulmonary hypertension
Table 10: Adcirca sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 11: Adempas drug profile
Table 12: Adempas pivotal trial data in pulmonary hypertension
Table 13: Adempas late-phase trial data in pulmonary arterial hypertension
Table 14: Adempas ongoing late-phase trials
Table 15: Adempas sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 16: INOpulse drug profile
Table 17: INOpulse Phase III trials in pulmonary arterial hypertension
Table 18: INOpulse Phase II data in pulmonary arterial hypertension
Table 19: INOpulse Phase II trials in PH-IPF
Table 20: INOpulse sales for pulmonary hypertension in the US ($m), 2016–25
Table 21: Letairis drug profile
Table 22: Letairis pivotal trial data in pulmonary arterial hypertension
Table 23: Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 24: Opsumit drug profile
Table 25: Opsumit pivotal trial data in pulmonary hypertension
Table 26: Opsumit late-phase trial data in pulmonary hypertension
Table 27: Opsumit ongoing late-phase trials in pulmonary hypertension
Table 28: Opsumit sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 29: Orenitram drug profile
Table 30: Orenitram pivotal trial data in pulmonary hypertension
Table 31: Orenitram late-phase data in pulmonary hypertension
Table 32: Orenitram ongoing late-phase trials in pulmonary hypertension
Table 33: Orenitram sales for pulmonary hypertension across the US and five major EU markets, by country ($m), 2016–25
Table 34: Remodulin drug profile
Table 35: Remodulin pivotal trial data in pulmonary hypertension
Table 36: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country ($m), 2016–25
Table 37: Revatio drug profile
Table 38: Revatio pivotal trial data in pulmonary hypertension
Table 39: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 40: Tracleer drug profile
Table 41: Tracleer pivotal trial data in pulmonary hypertension
Table 42: Tracleer sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 43: Tyvaso drug profile
Table 44: Tyvaso pivotal trial data in pulmonary hypertension
Table 45: Tyvaso ongoing late-phase trials in pulmonary hypertension
Table 46: Tyvaso sales for pulmonary hypertension in the US ($m), 2016–25
Table 47: Uptravi drug profile
Table 48: Uptravi pivotal trial data in pulmonary hypertension
Table 49: Uptravi ongoing late-phase trials in pulmonary hypertension
Table 50: Uptravi sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 51: Bardoxolone methyl drug profile
Table 52: Bardoxolone methyl Phase II data in pulmonary hypertension
Table 53: Bardoxolone methyl Phase III trials in pulmonary arterial hypertension
Table 54: Bardoxolone methyl sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 55: Esuberaprost drug profile
Table 56: Esuberaprost Phase II data in pulmonary arterial hypertension
Table 57: Esuberaprost Phase III trials in pulmonary arterial hypertension
Table 58: Esuberaprost sales for pulmonary hypertension in the US ($m), 2016–25
Table 59: Ralinepag drug profile
Table 60: Ralinepag Phase II data in pulmonary arterial hypertension
Table 61: Ralinepag sales for pulmonary hypertension across the US and five major EU markets, by country ($m), 2016–25
Table 62: Cardiologists and pulmonologists surveyed for the pulmonary hypertension primary research study, 2016
Table 63: Dana Point clinical classification of pulmonary hypertension
Table 64: Updated clinical classification of pulmonary arterial hypertension
Table 65: World Health Organization functional class definitions of pulmonary hypertension severity
Table 66: Approved treatments available for pulmonary hypertension across the US, Japan, and five major EU markets
Table 67: 2015 ESC/ERS recommendations for the treatment of pulmonary hypertension
Table 68: 2014 ACCP recommendations for the treatment of pulmonary arterial hypertension
Table 69: Treatment strategies for functional class I pulmonary arterial hypertension patients, by country (%)
Table 70: Patient share of approved drugs among functional class I pulmonary hypertension patients, by country (%)
Table 71: Patient share of drug classes as single and combination therapy among functional class I pulmonary hypertension patients, by country (%)
Table 72: Treatment strategies for functional class II pulmonary arterial hypertension patients, by country
Table 73: Patient share of approved drugs among functional class II pulmonary hypertension patients, by country (%)
Table 74: Patient share of drug classes as single and combination therapy among functional class II pulmonary hypertension patients, by country (%)
Table 75: Treatment strategies for functional class III pulmonary arterial hypertension patients, by country
Table 76: Patient share of approved drugs among functional class III pulmonary hypertension patients, by country (%)
Table 77: Patient share of drug classes as single and combination therapy among functional class III pulmonary hypertension patients, by country (%)
Table 78: Treatment strategies for functional class IV pulmonary arterial hypertension patients
Table 79: Patient share of approved drugs among functional class IV pulmonary hypertension patients, by country (%)
Table 80: Patient share of drug classes as single and combination therapy among functional class IV pulmonary hypertension patients, by country (%)
Table 81: Treatment strategies for pulmonary hypertension due to left heart disease patients, by country
Table 82: Patient share of approved drugs among pulmonary hypertension due to left heart disease patients, by country (%)
Table 83: Patient share of drug classes as single and combination therapy among pulmonary hypertension due to left heart disease patients, by country (%)
Table 84: Treatment strategies for pulmonary hypertension due to lung disease patients, by country
Table 85: Patient share of approved drugs among pulmonary hypertension due to lung disease patients, by country (%)
Table 86: Patient share of drug classes as single and combination therapy among pulmonary hypertension due to lung disease patients, by country (%)
Table 87: Treatment strategies for chronic thromboembolic pulmonary hypertension patients, by country
Table 88: Patient share of approved drugs among chronic thromboembolic pulmonary hypertension patients, by country (%)
Table 89: Patient share of drug classes as single and combination therapy among chronic thromboembolic pulmonary hypertension patients, by country (%)
Table 90: Treatment strategies for pulmonary hypertension with unclear and/or multifactorial mechanisms patients, by country
Table 91: Patient share of approved drugs among pulmonary hypertension with unclear and/or multifactorial mechanisms patients, by country (%)
Table 92: Patient share of drug classes as single and combination therapy among PH with unclear and/or multifactorial mechanisms patients, by country (%)
Table 93: Updated classification of pulmonary hypertension
Table 94: Sources used for the epidemiological analysis of pulmonary arterial hypertension in the US, Japan, and five major EU markets, by country
Table 95: Ratios of diagnosed pulmonary hypertension patients, by type and country
Table 96: Pulmonary arterial hypertension severity classification by NYHA functional class
Table 97: Diagnosed prevalent cases of PH in the US, Japan, and five major EU markets, by country, 2017–37
Table 98: Diagnosed prevalent cases of PAH (group 1) in the US, Japan, and five major EU markets, by country, 2017–37
Table 99: Diagnosed prevalent cases of PH due to left heart disease (group 2) in the US, Japan, and five major EU markets, by country, 2017–37
Table 100: Diagnosed prevalent cases of PH due to lung disease and/or hypoxia (group 3) in the US, Japan, and five major EU markets, by country, 2017–37
Table 101: Diagnosed prevalent cases of CTEPH (group 4) in the US, Japan, and five major EU markets, by country, 2017–37
Table 102: Diagnosed prevalent cases of PH with unclear multifactorial mechanisms (group 5) in the US, Japan, and five major EU markets, by country, 2017–37
Table 103: Profiled key marketed drugs for pulmonary hypertension
Table 104: Adcirca drug profile
Table 105: Adcirca pivotal trial data in pulmonary hypertension
Table 106: Adcirca sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 107: Adempas drug profile
Table 108: Adempas pivotal trial data in pulmonary hypertension
Table 109: Adempas late-phase trial data in pulmonary arterial hypertension
Table 110: Adempas ongoing late-phase trials
Table 111: Adempas sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 112: Letairis drug profile
Table 113: Letairis pivotal trial data in pulmonary arterial hypertension
Table 114: Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 115: Opsumit drug profile
Table 116: Opsumit pivotal trial data in pulmonary hypertension
Table 117: Opsumit late-phase trial data in pulmonary hypertension
Table 118: Opsumit ongoing late-phase trials in pulmonary hypertension
Table 119: Opsumit sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 120: Orenitram drug profile
Table 121: Orenitram pivotal trial data in pulmonary hypertension
Table 122: Orenitram late-phase data in pulmonary hypertension
Table 123: Orenitram ongoing late-phase trials in pulmonary hypertension
Table 124: Orenitram sales for pulmonary hypertension across the US and five major EU markets, by country ($m), 2016–25
Table 125: Remodulin drug profile
Table 126: Remodulin pivotal trial data in pulmonary hypertension
Table 127: Remodulin sales for pulmonary hypertension across the US, Japan, France, Germany, and Italy, by country ($m), 2016–25
Table 128: Revatio drug profile
Table 129: Revatio pivotal trial data in pulmonary hypertension
Table 130: Revatio sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 131: Tracleer drug profile
Table 132: Tracleer pivotal trial data in pulmonary hypertension
Table 133: Tracleer sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 134: Tyvaso drug profile
Table 135: Tyvaso pivotal trial data in pulmonary hypertension
Table 136: Tyvaso ongoing late-phase trials in pulmonary hypertension
Table 137: Tyvaso sales for pulmonary hypertension in the US ($m), 2016–25
Table 138: Uptravi drug profile
Table 139: Uptravi pivotal trial data in pulmonary hypertension
Table 140: Uptravi ongoing late-phase trials in pulmonary hypertension
Table 141: Uptravi sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 142: Profiled pipeline products in development for pulmonary hypertension
Table 143: Aurora-GT drug profile
Table 144: Aurora-GT Phase II trial in pulmonary hypertension
Table 145: INOpulse drug profile
Table 146: INOpulse Phase III trials in pulmonary arterial hypertension
Table 147: INOpulse Phase II data in pulmonary arterial hypertension
Table 148: INOpulse Phase II trials in PH-IPF
Table 149: INOpulse sales for pulmonary hypertension in the US ($m), 2016–25
Table 150: Bardoxolone methyl drug profile
Table 151: Bardoxolone methyl Phase II data in pulmonary hypertension
Table 152: Bardoxolone methyl Phase III trials in pulmonary arterial hypertension
Table 153: Bardoxolone methyl sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 154: Esuberaprost drug profile
Table 155: Esuberaprost Phase II data in pulmonary arterial hypertension
Table 156: Esuberaprost Phase III trials in pulmonary arterial hypertension
Table 157: Esuberaprost sales for pulmonary hypertension in the US ($m), 2016–25
Table 158: Ralinepag drug profile
Table 159: Ralinepag Phase II data in pulmonary arterial hypertension
Table 160: Ralinepag sales for pulmonary hypertension across the US and five major EU markets, by country ($m), 2016–25
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll